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INTRODUCTION

Despite years of intensive investigation into various aspects of the infection, as
well as substantial advances in medical and nursing care, including the development of potent antimicrobial chemotherapy, and the establishment of intensive care unit facilities, community-acquired pneumonia (CAP) continues to cause considerable morbidity and mortality worldwide. 1, 2 The use of adjunctive therapy, with agents that target diverse or specific components of disease pathogenesis represents a potential strategy to improve the poor outcome. [1] [2] [3] [4] To this end, various adjunctive therapies have
PATHOGENESIS OF CAP
The three most common causes of bacterial CAP are Streptococcus pneumoniae (the pneumococcus), Haemophilus influenzae and Moraxella catarrhalis. Collectively, these organisms account for >80% of cases of CAP, the pneumococcus being the predominant cause (>60% of cases). Colonization of the upper airways by these organisms is mediated via the interaction of bacterial surface adhesins with respiratory epithelium which is a prerequisite for development of invasive disease. During this phase, the organisms co-exist with the host, kept in check by host defenses and/or concealment in biofilm. 1 The transition of these airway colonists to menacing pathogens can be triggered by various events including:
 genotypic modifications leading to a more virulent phenotype  transmission to a suitably vulnerable, immunocompromised host  development by the host of an acute or chronic immunosuppressive viral infection.
The CAP pathogens utilize a range of predominantly protein virulence factors, to subvert innate and adaptive pulmonary host defenses, promoting invasion of the lower airways, as well as persistence and extra-pulmonary dissemination in severe disease. Well-characterized PRR families which recognize molecular structures common to IL-1β, IL-6, IL-8,IL-17, IL-18, TNF) . These, in turn, promote localized activation of vascular endothelium and presentation of chemoattractants enabling the transendothelial migration (TEM) of monocytes (M) and neutrophils (N), as well as exudation of proinflammatory complement proteins and acute phase reactants. Recruitment of these mobilizable, systemic elements of the innate immune system reinforces pulmonary host defenses. However, prolonged and misdirected inflammatory responses may intensify pulmonary damage via the excessive release of indiscriminate phagocyte-derived reactive oxygen species and proteases acting in tandem with microbial cytotoxins; these mechanisms may also favor the extrapulmonary dissemination of CAP pathogens and pro-inflammatory cytokines/chemokines resulting in a systemic inflammatory response with accompanying endothelial dysfunction and resultant exposure/release of factor VII, tissue factor, Von Willebrand factor, and sub-endothelial collagen, creating a pro-coagulant state.
microbial and viral pathogens, include : i) the Toll-like receptors (TLRs) and nucleotide oligomerization domain-like receptors (NLRs) of which there are at least 11 and 22 members respectively; ii) the inflammasomes, such as NLPR3, a subset of NLRs; and iii) the abundant cytosolic microbial and viral nucleic acid sensors. 8, 9 However, should these mechanisms be overcome by CAP organisms, the resultant sustained and ineffective pulmonary inflammatory response, in concert with bacterial toxins, predisposes to acute respiratory distress syndrome/ acute lung injury.
These events in turn also promote extrapulmonary dissemination of the pathogens and their pro-inflammatory products leading to a systemic inflammatory response with accompanying endothelial dysfunction and a pro-coagulant state. The consequences include the potential for the development of acute coronary events, as discussed more fully below, as well as septic shock and multiorgan dysfunction syndrome. 1 A generic scheme summarizing these mechanisms is shown in Figure 1 .
CAP, ACUTE CARDIAC EVENTS AND PLATELET ACTIVATION
With respect to CAP-associated cardiovascular disorders, the increased risk for cardiac events in hospitalized patients may be as high as 8-fold in the 15 day period following admission, and greatest (100-fold increased risk) within the first 2 -3 days. 6 Incident cardiac complications associated with increased morbidity and mortality include myocardial infarction (MI, predominantly silent) and new or worsening heart failure or arrhythmias, with the major risk factors being older age, nursing home residence, preexisting chronic respiratory or cardiovascular conditions, severity of CAP, and smoking. 6, 7 In addition to the mechanisms described above, a recent study by Cangemi et al.
has implicated direct effects of CAP pathogens on platelet activation in the pathogenesis of myocardial infarction, providing insights into potential adjunctive antithrombotic strategies.  amplification of platelet activation by several strains of bacteria belonging to the Staphylococcus and Streptococcus genera may also result from their interaction with the platelet α-granule protein, platelet factor-4 (PF4, CXCL4), a prothrombotic, CXC chemokine which also possesses antibacterial activity. 13, 14 Pathogen-bound PF4 is recognized by circulating immunoglobulin G, forming a complex which binds to the platelet FcγRIIA receptor, potentiating GPIIb/IIIa activation by mechanisms which remain to be fully characterized, but appear to involve Src and Syk tyrosine kinases.
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 In rodent and murine models of experimental infection, sustained infection with the pneumococcus has been found to trigger atherogenesis and worsen cerebral ischemia via an interleukin (IL)-1/glycoprotein (GP)Ibα-dependent mechanism, probably due to inflammasome activation, resulting in platelet activation and microvascular coagulation. 15 Additional mechanisms which may contribute to CAP-associated myocardial infarction include the heterotypic interactions of platelets with neutrophils and vascular receptors. Platelet factor-4 (PF4), released via mobilization of intracellular granules, also contributes to platelet activation. This involves interaction of PF4 with CAP pathogens followed by binding of IgG to form a complex, which binds to the platelet FcγRIIA receptor, resulting in activation of the platelet integrin, GPIIb/IIIa (alpha IIb beta 3). In addition to activation of GPIIb/IIIa, these various mechanisms of platelet activation also result in upregulated expression/activation of various other platelet adhesion molecules (GPIbα, P selectin, CD40L, ICAM-2) which promote homotypic and/or heterotypic platelet aggregation. In the case of the former, homotypic aggregation results in platelet plug formation. With respect to heterotypic aggregation, the binding of platelets to neutrophils intensifies neutrophil activation, causing binding to and damage of vascular endothelium, thereby potentiating platelet activation and thrombus formation via exposure of, and contact with sub-endothelial connective tissue.
The inhibitory actions of statins on these processes are denoted by the intersecting double lines (=).
endothelium. Activated platelets form stable clusters around neutrophils, a phenomenon known as "satallitism," involving multiple pro-adhesive mechanisms. 16 These include interactions of P-selectin, CD40L, intercellular adhesion molecule-2 (ICAM-2) and
GPIbα on platelets with their respective ligands on neutrophils (P-selectin GP ligand-1, CD40, and the β2-integrins CD11a/CD18 and CD11b/CD18). 17, 18 These interactions not only promote adhesion of neutrophils to activated vascular endothelium and transendothelial migration, but also sensitize the pro-oxidative and pro-inflammatory activities of these cells, predisposing to endothelial damage and dysfunction, potentially exacerbating microvascular coagulation. In addition, the presentation by activated platelets of the DNA-binding cytokine, high mobility group box 1 protein (HMGB1) to neutrophils has been reported to promote the formation of neutrophil extracellular traps, 19 leading to further endothelial dysfunction due to histone-mediated damage 20 and thrombin generation. 21 These mechanisms of pathogen-associated platelet activation are shown in Figure 2 .
ALTERNATIVE MECHANISMS OF CAP-ASSOCIATED CARDIAC EVENTS
Experimental studies in mice and macaques have revealed that invasive pneumococcal disease leads to translocation of the pneumococcus into the myocardium resulting in the formation of "unique microlesions that disrupt cardiac function." 22 Bacterial translocation into the heart and formation of microlesions were found to be dependent on the pneumococcal adhesin, choline-binding protein A (CbpA) and the cholesterol-binding, pore-forming cytotoxin, pneumolysin, respectively. 22 In this context it is noteworthy that statin therapy of severe pneumococcal infection in a murine model of sickle cell disease was found to confer protection against the cytolytic actions of pneumolysin by apparent interference with toxin/membrane cholesterol interactions.
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THERAPEUTIC IMPLICATIONS
Among the myriad of adjunctive therapies that have been studied, the three major options are the macrolides, corticosteroids and statins, all of which have been documented to possess anti-inflammatory activities, targeting various cell types and their mediators, and, to a greater or lesser extent, to have antiplatelet effects.
Macrolides
The majority of the publications describing patient outcome with the use of macrolide-based antibiotic regimens have documented clinical benefit in patients with CAP, particularly in the more severely ill cases. 24, 25 Macrolides have been documented not only to possess adjunctive anti-inflammatory, immunomodulatory activity in vitro, but also to inhibit platelet-activating factor (PAF)-mediated platelet aggregation. 26 Although these activities may underpin the benefits of these agents in the management of CAP, differentiating them from antimicrobial activity in the clinical setting is very difficult.
7
Corticosteroids
The evidence for corticosteroid adjunctive therapy has been less clear-cut, although recent meta-analyses and studies have shown benefit, particularly in the severe CAP subgroup, and especially in the presence of septic shock or with prolonged use of these agents. [27] [28] [29] [30] Two randomized placebo-controlled studies have recently been reported. 31, 32 The former study among hospitalized adults with CAP documented a shorter time to clinical stability in patients receiving adjunctive prednisone for 7 days. 31 The latter study among patients with severe CAP and high initial inflammatory response (C-reactive protein > 150mg/l) documented less treatment failure with the use of adjunctive methylprednisolone therapy for 5 days. 32 Another recent study, confirming several earlier reports of the use of prednisolone or methylprednisolone in children with complicated Mycoplasma pneumoniae pneumonia, documented rapid defervescence of infection in most children (86/90 cases) receiving one of these agents as adjunctive therapy. 33 Interestingly, prednisolone, which appears to be the most effective corticosteroid in the adjunctive therapy of CAP, has been reported to inhibit platelet activation in vitro by a non-genomic mechanism not shared with other types of corticosteroid. 34 Notwithstanding the fact that some patients who develop CAP may be taking long-term corticosteroids (e.g. inhaled corticosteroids) or macrolides, the studies evaluating the use of these agents as adjunctive therapy in CAP, have been done with the use of these agents as acute therapies.
Statins
The statins are lipid-lowering drugs used primarily for the prevention and treatment of cardiac conditions. 35 They have a variety of well-characterized pleiotropic effects, including anti-inflammatory and immunomodulatory activities that may contribute to their effectiveness against cardiac disease. experimental studies and 17 clinical studies were included in the analysis. 35 In the experimental setting the findings were as follows: i) a reduction in release of proinflammatory chemokines and cytokines in patients with CAP, in both the pulmonary and systemic compartments; ii) a reduction in activation and recruitment of neutrophils to the lungs after injury to the lungs; and iii) protection of the host from lung injury associated with the lower respiratory tract infection by attenuation of disruption of the pulmonary vasculature. 35 Evaluation of the clinical studies indicated the following: i) a decreased risk of pneumonia in individuals on statins was documented in most studies;
and ii) current statin use was mostly associated with improved survival of pneumonia.
It is important to note, however, that most clinical studies with statins were done in the situation in which patients were currently taking these agents for their lipidlowering and cardiovascular effects and their risk of acquiring CAP, and the effects of statin use on outcome, once CAP occurred, were compared to matched patients not taking statins. One exception appears to be a study in which the impact of statin administration on day 1 and 2 of hospital admission to patients with pneumonia resulted in a modest benefit on mortality in cases not admitted to the intensive care unit. 51 These findings are consistent with a rapid onset of cardioprotective and anti-inflammatory action of statins, as reviewed previously. 52 However, a second randomized, placebocontrolled study of statin administration to hospitalized patients with CAP failed to document either a clinical benefit, or a reduction in inflammatory cytokines at 48 hours. 53 With respect to case control and cohort studies, these have documented that current statin use was associated with a decreased risk of hospitalization for pneumonia and lower 30 day mortality, 54 as well as lower mortality during the 6 month period following pneumonia. 55 A retrospective cohort study documented that statin use was associated with decreased mortality in patients with pneumococcal pneumonia on days 7, 14, 20 and 30. 56 Interestingly, in the latter study, mortality was not decreased in patients given a macrolide for therapy, nor in those on a macrolide as well as a statin compared with those not on a macrolide. One retrospective observational cohort study documented that patients who received a statin on day 1 or day 2 of hospital admission for pneumonia had a moderate reduction in mortality among cases not admitted to the intensive care unit. 57 Three additional systematic reviews and meta-analyses have been published recently interrogating the potential benefit of statins in the prevention and/or mortality of CAP. [58] [59] [60] While all showed benefit in one or more of the endpoints, all three indicated the need for caution in the interpretation of the data due to a number of reasons, including low quality of evidence (observational study designs, heterogeneity, publication bias), weakening of the association in important subgroups accounting for patient differences (e.g. severity of illness, smoking and vaccination status) and in studies with greater methodological rigor, and substantial statistical and clinical heterogeneity. [58] [59] [60] Another consideration is the potential confounding that may be associated with the so-called "healthy user effect", which suggests that statin users may be more health conscious than non-users and the clinical benefits seen may relate to a healthier lifestyle and greater compliance with both statin use and other preventative health measures rather than to the use of statins per se.
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Anti-platelet agents
There is a paucity of definitive studies documenting the potential benefits of anti-platelet agents on CAP outcomes. 61 In the recent study by Cangemi et al. mentioned above, administration of aspirin at a dose of 100mg per day had no effect on either platelet activation or the occurrence of cardiovascular events in patients with pneumonia. 10 These authors suggest that the dose of aspirin they used may have been inadequate and propose that additional dose-ranging studies be undertaken. A single study of patients on prior clopidogrel therapy showed trends towards both an increased incidence of CAP, as well as a decrease in its severity, without controlling for aspirin use. 62 An integrated scheme of the likely sites of the therapeutic activities of statins and the other adjunctive therapies, as well as those of the selective antiplatelet agents listed in Table 1 , is shown in Figure 3 . optimal dose that is required, and the optimal duration of treatment to achieve these effects. While similar considerations also apply to all of the other adjunctive therapies described, there is a particular dearth of information regarding the selective anti-platelet agents with regard to their cardioprotective potential in the setting of CAP. Furthermore, future studies should also focus on combinations of the various adjunctive agents. All these questions are best answered by well-designed randomized controlled trials.
